Roundtable

Management of Patients With Treatment-Resistant Metastatic Prostate Cancer

The following is a lightly edited transcript of a teleconference recorded in December 2018. It follows up on previous prostate-cancer discussions on survivorship (Aronson WJ, Nickols NG, Neymark A, Glassman P. Coordination of care between primary care and oncology for patients with prostate cancer. Fed Pract. 2018;35[5]:S18-S23.) and first-line treatments (Aronson WJ, Graff JN, Houranieh JM, Nickols NG. Treatment and management of patients with prostate cancer. Fed Pract. 2017;34[suppl 3]:S35-S41).


 

References

Sequencing Therapies

Mark Klein, MD. The last few years, there have been several new trials in prostate cancer for people in a metastatic setting or more advanced local setting, such as the STAMPEDE, LATITUDE, and CHAARTED trials. 1-4 In addition, recently a few trials have examined apalutamide and enzalutamide for people who have had PSA (prostate-specific antigen) levels rapidly rising within about 10 months or so. One of the questions that arises is, how do we wrap our heads around sequencing these therapies. Is there a sequence that we should be doing and thinking about upfront and how do the different trials compare?

Click here to continue reading

Next Article: